Sonova Holding AG (SONVY)
57.13
+1.09
(+1.94%)
USD |
OTCM |
May 02, 16:00
Sonova Debt to Equity Ratio: 0.00 for Sept. 30, 2023
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2023 | 0.00 |
| March 31, 2023 | 0.6861 |
| September 30, 2022 | 0.00 |
| March 31, 2022 | 0.4978 |
| September 30, 2021 | 0.00 |
| March 31, 2021 | 0.5686 |
| September 30, 2020 | 0.00 |
| March 31, 2020 | 0.3925 |
| September 30, 2019 | 0.00 |
| March 31, 2019 | 0.2591 |
| September 30, 2018 | 0.00 |
| March 31, 2018 | 0.3097 |
| September 30, 2017 | 0.00 |
| March 31, 2017 | 0.3601 |
| Date | Value |
|---|---|
| September 30, 2016 | 0.00 |
| March 31, 2016 | 0.0001 |
| September 30, 2015 | 0.00 |
| March 31, 2015 | 0.0001 |
| September 30, 2014 | 0.00 |
| March 31, 2014 | 0.0458 |
| September 30, 2013 | 0.00 |
| March 31, 2013 | 0.142 |
| September 30, 2012 | 0.00 |
| March 31, 2012 | 0.00 |
| September 30, 2011 | 0.0161 |
| March 31, 2011 | 0.2001 |
| September 30, 2010 | 0.0578 |
| March 31, 2010 | 0.372 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Sep 2019
0.6861
Maximum
Mar 2023
0.2383
Average
--
Median
Sep 2019
Debt to Equity Ratio Benchmarks
| AC Immune SA | 0.00 |
| CRISPR Therapeutics AG | 0.00 |
| Addex Therapeutics Ltd | 0.00 |
| NLS Pharmaceutics Ltd | -- |
| Molecular Partners AG | 0.00 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 5.888B |
| Total Liabilities (Quarterly) | 3.559B |
| Shareholders Equity (Quarterly) | 2.307B |
| Current Ratio | 1.295 |
| Net Debt Paydown Yield | 3.08% |